corporate profile

Novocure (NASDAQ: NVCR) is a global oncology company striving to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields (TTFields). Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma (GBM) and for the treatment of adult patients with malignant pleural mesothelioma (MPM). In the U.S., our GBM therapy is approved by the U.S. Food and Drug Administration (FDA) under the Premarket Approval (PMA) pathway, and our MPM therapy is approved by the FDA under the Humanitarian Device Exemption (HDE) pathway. We continue to explore the safety and efficacy of TTFields for the treatment of multiple solid tumor cancers of the brain, thorax and abdomen.

corporate presentation clinical evidence
3
FDA-approved indications
30,000+
patients treated through January 2024
$509M
annual net revenues (2023)
$223M
annual R&D investments (2023)
4
ongoing phase 3 trials
view all

latest filings

date filing type filing download
June 09, 2024 8-K Current report filing
June 06, 2024 4 Statement of Changes in Beneficial Ownership
June 05, 2024 4 Statement of Changes in Beneficial Ownership
June 05, 2024 4 Statement of Changes in Beneficial Ownership
June 05, 2024 4 Statement of Changes in Beneficial Ownership
June 05, 2024 4 Statement of Changes in Beneficial Ownership
June 05, 2024 4 Statement of Changes in Beneficial Ownership
June 05, 2024 4 Statement of Changes in Beneficial Ownership
June 05, 2024 4 Statement of Changes in Beneficial Ownership
June 05, 2024 4 Statement of Changes in Beneficial Ownership
May 19, 2024 8-K Current report filing
May 01, 2024 10-Q Quarterly Report
May 01, 2024 8-K Current report filing
April 21, 2024 DEFA14A Additional Proxy Soliciting Materials (definitive)
April 21, 2024 DEF 14A Proxy Statement (definitive)
mission, vision and values

mission

Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.

vision

Patient-forward: aspiring to make a difference in cancer

learn more

contact us

investorinfo@novocure.com
610-723-7427

sign up for email alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.

"*" indicates required fields

List
This field is for validation purposes and should be left unchanged.